NEULANDLAB vs WOCKPHARMA: Stock Comparison

Neuland Laboratories Limited vs Wockhardt Ltd

Live data: 22 July 2026, 3:04 PM IST • Source: NSE and company filings

Wockhardt Ltd is the larger company by market capitalisation. Neuland Laboratories Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Neuland Laboratories Limited and Wockhardt Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, NEULANDLAB is more favourable on 11 of 13 scored metrics and WOCKPHARMA on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,362 Cr vs ₹23,702 Cr
P/E Ratio
NEULANDLAB has a lower P/E
66.58x vs 144.46x
P/B Ratio
WOCKPHARMA has a lower P/B
6.23x vs 12.93x
EPS
NEULANDLAB has higher earnings per share
₹293.13 vs ₹13.1
Dividend Yield
NEULANDLAB has a higher dividend yield
0.06% vs 0%
Revenue Growth (TTM YoY)
NEULANDLAB has faster revenue growth
136.4% vs 26%
EPS Growth (TTM YoY)
NEULANDLAB has faster EPS growth
664.4% vs 0%
Qtr Sales Growth
NEULANDLAB has stronger quarterly sales growth
136% vs 29.9%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricNEULANDLABWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricNEULANDLABWOCKPHARMA
Live Price₹18,461₹1,864
Day Change-2.3%-1.7%
Volume15,0397.24 L
52-Week High₹20,089₹2,422.3
52-Week Low₹11,500₹1,086.7
Distance from 52W High-8.1%-23.05%

Valuation

MetricNEULANDLABWOCKPHARMA
Market Cap₹23,702 Cr₹30,362 Cr
P/E Ratio66.58x144.46x
P/B Ratio12.93x6.23x
EPS₹293.13₹13.1
Book Value₹1,460.02₹304
Dividend Yield0.06%0%

Growth

MetricNEULANDLABWOCKPHARMA
Revenue Growth (TTM YoY)136.4%26%
EPS Growth (TTM YoY)664.4%0%
Qtr Sales Growth136%29.9%
Qtr Profit Growth665%688%

Profitability & Leverage

MetricNEULANDLABWOCKPHARMA
ROE21.4%6.11%
ROCE26.6%7.55%
Net Margin17.99%3.3%
Operating Margin28.4%19.3%
Debt to Equity0.16x0.45x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricNEULANDLABWOCKPHARMA
Promoter Holding32.63%49.08%
FII Holding20.46% 0.44 pp7.09% 0.1 pp
DII Holding15.84% 1.13 pp10.96% 0.41 pp
Public Holding31.07% 0.69 pp32.83% 0.52 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Neuland Laboratories Limited and Wockhardt Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.